Published in NMR Biomed on June 01, 2005
Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn (2008) 2.51
The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci (2006) 1.63
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med (2012) 1.06
Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol (2011) 1.02
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer (2007) 0.98
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer (2009) 0.95
The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia (2006) 0.91
Short-term temperature effect on the HRMAS spectra of human brain tumor biopsies and their pattern recognition analysis. MAGMA (2010) 0.80
Minimization of spectral pattern changes during HRMAS experiments at 37 degrees celsius by prior focused microwave irradiation. MAGMA (2012) 0.79
Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy. J Transl Med (2015) 0.79
N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice. Br J Cancer (2007) 0.77
Response to Comments on "Magnetic Resonance Spectroscopy Identifies Neural Progenitor Cells in the Live Human Brain". Science (2008) 0.76
Nuclear magnetic resonance spectroscopy is highly sensitive for lipid-soluble metabolites. Neural Regen Res (2013) 0.75
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics (2007) 6.93
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Human metabolic phenotype diversity and its association with diet and blood pressure. Nature (2008) 5.41
Systems biology: Metabonomics. Nature (2008) 5.32
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Toward interoperable bioscience data. Nat Genet (2012) 4.72
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol (2007) 3.68
Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 3.45
Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut (2011) 3.42
MetaboLights--an open-access general-purpose repository for metabolomics studies and associated meta-data. Nucleic Acids Res (2012) 3.32
Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med (2013) 3.26
Mapping the Arabidopsis organelle proteome. Proc Natl Acad Sci U S A (2006) 3.03
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Metabolic phenotyping in health and disease. Cell (2008) 2.80
Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov (2008) 2.59
The metabolomics standards initiative. Nat Biotechnol (2007) 2.54
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A (2010) 2.52
Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev (2010) 2.50
Gut microbiome-host interactions in health and disease. Genome Med (2011) 2.48
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res (2003) 2.25
Oxygenation and hematocrit dependence of transverse relaxation rates of blood at 3T. Magn Reson Med (2007) 2.22
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol (2008) 2.17
UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom (2006) 2.17
NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed (2005) 2.15
Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med (2012) 2.13
Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A (2004) 2.11
Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res (2009) 2.10
Proton transfer ratio, lactate, and intracellular pH in acute cerebral ischemia. Magn Reson Med (2007) 2.09
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07
Real-time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J (2009) 2.05
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal Chem (2011) 2.02
Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol (2006) 1.99
How has healthcare research performance been assessed?: a systematic review. J R Soc Med (2011) 1.97
Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res (2006) 1.96
High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res (2005) 1.93
Metabonomics in pharmaceutical R&D. FEBS J (2007) 1.93
The human gut microbiome: implications for future health care. Curr Gastroenterol Rep (2008) 1.84
Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res (2010) 1.84
A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet (2011) 1.83
Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem (2006) 1.81
Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004) 1.79
Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Proteome Res (2008) 1.78
NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol (2008) 1.77
Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem (2006) 1.76
High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc (2010) 1.76
Melamine-induced renal toxicity is mediated by the gut microbiota. Sci Transl Med (2013) 1.75
Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol (2011) 1.72
Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab (2007) 1.71
Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res (2008) 1.67
Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet (2007) 1.66
Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst (2003) 1.65
In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med (2004) 1.65
Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto Calif) (2008) 1.63
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. Am J Pathol (2002) 1.62
Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem (2006) 1.61
Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol (2011) 1.60
Recursive segment-wise peak alignment of biological (1)h NMR spectra for improved metabolic biomarker recovery. Anal Chem (2009) 1.59
Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies. Ann Surg (2014) 1.58
Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res (2009) 1.57
Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab (2012) 1.55
Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res (2006) 1.55
A constrained least-squares approach to the automated quantitation of in vivo ¹H magnetic resonance spectroscopy data. Magn Reson Med (2011) 1.54
MetaboLights: towards a new COSMOS of metabolomics data management. Metabolomics (2012) 1.53
Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2009) 1.53
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med (2014) 1.53
Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics (2007) 1.51
Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. Anal Biochem (2004) 1.51
Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res (2010) 1.50
Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med (2006) 1.49
Coordinated multitissue transcriptional and plasma metabonomic profiles following acute caloric restriction in mice. Physiol Genomics (2006) 1.47
Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med (2012) 1.45
So what's the deal with metabonomics? Anal Chem (2003) 1.43
A metabonomic strategy for the detection of the metabolic effects of chamomile (Matricaria recutita L.) ingestion. J Agric Food Chem (2005) 1.42
NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem Res Toxicol (2003) 1.42
Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. Physiol Genomics (2006) 1.42
Deletion of btn1, an orthologue of CLN3, increases glycolysis and perturbs amino acid metabolism in the fission yeast model of Batten disease. Mol Biosyst (2010) 1.42
The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics (2005) 1.41
High-throughput 1H NMR-based metabolic analysis of human serum and urine for large-scale epidemiological studies: validation study. Int J Epidemiol (2008) 1.39
Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res (2003) 1.38
The comparison of plasma deproteinization methods for the detection of low-molecular-weight metabolites by (1)H nuclear magnetic resonance spectroscopy. Anal Biochem (2002) 1.38
A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics (2006) 1.34
Progression of neuronal damage after status epilepticus and during spontaneous seizures in a rat model of temporal lobe epilepsy. Prog Brain Res (2002) 1.32
Quantitative T(1rho) and adiabatic Carr-Purcell T2 magnetic resonance imaging of human occipital lobe at 4 T. Magn Reson Med (2005) 1.32
Nephrocalcinosis (enamel renal syndrome) caused by autosomal recessive FAM20A mutations. Nephron Physiol (2013) 1.31
Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol (2010) 1.31
An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol (2003) 1.30
Optimization and evaluation of metabolite extraction protocols for untargeted metabolic profiling of liver samples by UPLC-MS. Anal Chem (2010) 1.30